06/05/2014 12:19 PM Posted by: Dr. H. Alejandro Preti
Annual Meeting ASCO excerpts
02/03/2014 05:50 PM Posted by: Dr. H. Alejandro Preti
The future of PD-1 and PD-L1 inhibitors in non-small cell lung cancer looks bright.
06/23/2013 10:08 AM Posted by: Dr. H. Alejandro Preti
Dr. Pazdur's position and the FDA drug approval process.
Categoried under: FDA Approval
04/21/2013 02:05 PM Posted by: Dr. H. Alejandro Preti
Immunoconjugates like Brentuximab Vedotin (Adcetris) and TDM-1 (Kadcyla)
04/04/2013 08:38 AM Posted by: Dr. H. Alejandro Preti
Categoried under: Clinical Trials
03/24/2011 01:39 PM Posted by: Dr. H. Alejandro Preti
¿Por qué vienen los pacientes de Latino América a Houston a verlo? ¿Qué ventajas tiene un paciente que se atiende con el Dr. Preti?
Categoried under: Novedades sobre el Cáncer
11/19/2009 09:50 AM Posted by: Dr. H. Alejandro Preti
Value of mammograms as screening tools debate.
Categoried under: Cancer News
11/10/2009 06:46 PM Posted by: Dr. H. Alejandro Preti
As the war on cancer enters its fifth decade, 51 studies stood out as examples of progress that occurred in the past year, as determined by the American Society of Clinical Oncology (ASCO) and reported in "Clinical Cancer Advances 2009." Reflecting input from specialists throughout the field, the ASCO annual report highlights research developments for nine types of cancer, as well as cancer disparities, quality of life and quality of care, and cancer prevention and screening. "As this report demonstrates -- and as history shows -- investment in clinical cancer research pays off," ASCO president Douglas Blayney, MD, of the University of Michigan in Ann Arbor, said in a statement included in the report. "Since 1990, cancer mortality rates have declined by 15%. Today, two-thirds of patients survive at least five years after diagnosis, compared to just half of patients 40 years ago." "Thanks to basic research advances, we are entering an era of personalized cancer medicine, in which treatment is tailored to the unique genetics of the individual," Blayney added. The entire report appears online in the Journal of Clinical Oncology, but here is a summary of developments related to some of the most common cancers. In an attempt to provide context and a diversity of viewpoints, MedPage Today, in collaboration with ABC News, solicited comments from cancer specialists who were not involved in developing the ASCO publication. As appropriate, their views are included with the review of cancer research highlights.
Soon to open "Phase II Study of Combination Vorinostat and Bortezomib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma"
10/22/2009 02:32 PM Posted by: Dr. H. Alejandro Preti
Primary Objective of Clinical Trial: To determine the response rates of patients with relapsed and/or refractory non Hodgkin lymphoma treated with a combination of Vorinostat and Bortezomib.
7Cancer NewsCancer News (3)
1Clinical TrialsClinical Trials (3)
6FDA ApprovalFDA Approval (2)
8Novedades sobre el CáncerNovedades sobre el Cáncer (8)
2Oncology StudyOncology Study (1)
3Relapsed and/or Refractory Non-Hodgkin Lymphoma (NHL)Relapsed and/or Refractory Non-Hodgkin Lymphoma (NHL) (1)
201406June1June 2014 (1)
201402February1February 2014 (1)
201308August1August 2013 (1)
201306June1June 2013 (1)
201304April2April 2013 (2)
201302February1February 2013 (1)
201110October4October 2011 (4)
201109September1September 2011 (1)
201108August2August 2011 (2)
201104April3April 2011 (3)
201103March2March 2011 (2)
201102February1February 2011 (1)
201011November1November 2010 (1)
201006June1June 2010 (1)
201003March1March 2010 (1)
201001January1January 2010 (1)
200912December1December 2009 (1)
200911November2November 2009 (2)
200910October1October 2009 (1)